Cite

HARVARD Citation

    Baldacci, S. et al. (2022). Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. European journal of cancer. pp. 51-59. [Online]. 
  
Back to record